Status:
COMPLETED
Mitochondrial DNA and Nuclear SNPs to Predict Severity of COVID-19 Infection
Lead Sponsor:
Maastricht University
Collaborating Sponsors:
Innovative Medicines Initiative
Conditions:
Covid19
Eligibility:
All Genders
18+ years
Brief Summary
In December 2019, the first people got infected with COVID-19 in Wuhan, China. Within weeks, this highly infectious disease spread all over the world. Nearly one year later everyone is still trying to...
Detailed Description
In December 2019, the first cases of coronavirus disease 2019 (COVID-19) were diagnosed in Wuhan, China. Within a couple of weeks, the highly contagious disease spread across the world, requiring rapi...
Eligibility Criteria
Inclusion
- Confirmed COVID-19 disease
- Age at least 18 years
- Willing and able to provide a saliva sample
- Able to understand the patient study information
- Signed informed consent
Exclusion
- Exclusion criteria for hospitalized patients
- Severe illness other than COVID-19 at hospital admission Exclusion criteria for non-hospitalized patients
- Severe COVID-19 illness leading to death or requiring active treatment without hospital admission
Key Trial Info
Start Date :
April 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 12 2023
Estimated Enrollment :
394 Patients enrolled
Trial Details
Trial ID
NCT04750330
Start Date
April 1 2021
End Date
June 12 2023
Last Update
June 15 2023
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Regional Chest Diseases Hospital of Athens <Sotiria>
Athens, Greece
2
University of Florence
Florence, Italy
3
Centro Hospitalar de Setúbal
Setúbal, Portugal